Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 30, 2019 - Issue 5
Submit an article Journal homepage
1,608
Views
6
CrossRef citations to date
0
Altmetric
Psoriasis

Treating moderate plaque psoriasis: prospective 6-month chart review of patients treated with apremilast

Melissa L. F. KnucklesPrivate Practice, Corbin, KY and Richmond, KY, USA; Correspondence[email protected]
View further author information
,
Eugenia LeviCelgene Corporation, Summit, NJ, USA; View further author information
&
Jennifer SoungSouthern California Dermatology, Santa Ana, CA, USAView further author information
Pages 430-434 | Received 01 Jun 2018, Accepted 31 Jul 2018, Published online: 26 Nov 2018

References

  • Otezla [package insert]. Summit (NJ): Celgene Corporation; June 2017.
  • Oral Otezla® (apremilast) approved by the European Commission for the treatment of both patients with psoriasis and psoriatic arthritis [press release]. Celgene Corporation; 2015. Accessed March 14, 2017. Available from: http://files.shareholder.com/downloads/AMDA-262QUJ/3977267429x0x803746/56511ED3-7864-49A1-8BD3-C5C5B9116DE5/CELG_News_2015_1_16_General_Releases.pdf
  • Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM 1]). J Am Acad Dermatol. 2015;73:37–49.
  • Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2). Br J Dermatol. 2015;173:1387–1399.
  • Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65:137–174.
  • Armstrong AW, Robertson AD, Wu J, et al. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003–2011. JAMA Dermatol. 2013;149:1180–1185.
  • Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70:871–881.
  • Armstrong AW, Koning JW, Rowse S, et al. Under-treatment of patients with moderate to severe psoriasis in the United States: analysis of medication usage with health plan data. Dermatol Ther (Heidelb). 2017;7:97–109.
  • Strober B, Bagel J, Lebwohl M, et al. Efficacy and safety of apremilast in patients with moderate plaque psoriasis with lower BSA: week 16 results from the UNVEIL study. J Drugs Dermatol. 2017;16:801–808.
  • Stein Gold L, Bagel J, Lebwohl M, et al. Efficacy and safety of apremilast in systemic- and biologic-naive patients with moderate plaque psoriasis: 52-week results of UNVEIL. J Drugs Dermatol. 2018;17:221–228.
  • Knuckles MLF, Levi E, Soung J. Defining and treating moderate plaque psoriasis: a dermatologist survey. J Dermatolog Treat. 2018;29:1–6.
  • Richards HL, Fortune DG, Griffiths CE. Adherence to treatment in patients with psoriasis. J Eur Acad Dermatol Venereol. 2006;20:370–379.
  • Helmick CG, Lee-Han H, Hirsch SC, et al. Prevalence of psoriasis among adults in the U.S.: 2003–2006 and 2009–2010 National Health and Nutrition Examination Surveys. Am J Prev Med. 2014;47:37–45.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.